Notice regarding 100% share acquisition of LOMA Holding GmbH, a German pharmaceutical contract development and manufacturing organization
1st Quarter Consolidated Financial Results for the Year Ending March 31, 2019 
（128.1K）
Presentation for 1st Quarter Consolidated Financial Results for the Year Ending March 31, 2019 （952.0K）
PARTIAL REVISIONS OF NOTICE OF THE 152ND ANNUAL GENERAL MEETING OF SHAREHOLDERS(2) （76.0K）
NOTICE OF THE 152ND ANNUAL GENERAL MEETING OF SHAREHOLDERS （200.8K）
PARTIAL REVISIONS OF NOTICE OF THE 152ND ANNUAL GENERAL MEETING OF SHAREHOLDERS （76.9K）
Pharmaceutical Excipient “GRANFILLER-D®”Listed in “Japanese Pharmaceutical Excipients 2018”
Recognized as “2018 Certified Health & Productivity Management Outstanding Organization ~WHITE 500~”
Price Revision of Peracetic Acid Derivatives
Recovery and Operating Situation of Peracetic Acid Plant at Ohtake Plant(Fire Accident at Ohtake Plant: 5th Report)
Daicel to be responsible for marketing of Genomatica’s biobased 1,3-butylene glycol in Asia-Pacific （318.1K）
Outlook for Recovery of Peracetic Acid Plant of the Ohtake Plant (Follow-up Report)
Hitachi and Daicel Develop Management and Manufacturing Dashboard by Utilizing IoT to Integrally Visualize KPIs from Management Information to Manufacturing Workplaces’ Situations （299.4K）
Fire Accident at Ohtake Plant (Follow-up Report) （188.3K）
Apology for Fire Accident at Ohtake Plant （221.6K）
Collaborative Relationship and Capital Alliance With Toyoda Gosei （85.7K）
“3D-Ⅲ” — Our New Mid-Term Business Plan
Sept. 8, 2019
Daicel 100th Anniversary
